HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes.
HER2
biomarkers
colorectal cancer
pathology
targeted therapy
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
received:
17
08
2022
revised:
02
09
2022
accepted:
06
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
HER2 is an emerging biomarker in colorectal cancer (CRC). This oncogene plays an essential role in regulating cell proliferation, differentiation, migration, and, more in general, tumorigenesis and tumor progression. The most frequent types of HER2 alterations in CRC include gene amplification and missense mutations in 7-8% of CRC, often being mirrored by HER2 protein overexpression, representing founder events in solid tumors, including CRC. There are currently no approved HER2-targeted therapy guidelines for CRC; however, several studies have shown that HER2 can be effectively targeted in meta-static CRC settings. In this review, we discuss the current knowledge of HER2 testing in CRC and the immediate future perspectives for HER2 targeting in the metastatic setting.
Identifiants
pubmed: 36143438
pii: life12091403
doi: 10.3390/life12091403
pmc: PMC9502498
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente 2021
Références
Eur J Pharm Sci. 2017 Dec 15;110:51-61
pubmed: 28115222
Br J Cancer. 2022 Sep;127(5):811-823
pubmed: 35637411
Clin Pharmacol Drug Dev. 2013 Jan;2(1):11-24
pubmed: 27121556
Clin Cancer Res. 2021 Mar 15;27(6):1612-1622
pubmed: 33203645
Cancer Drug Resist. 2022 Sep 1;5(4):882-888
pubmed: 36627898
J Natl Cancer Inst. 2018 Dec 1;110(12):1409-1417
pubmed: 29718453
Int J Mol Sci. 2017 Jun 21;18(6):
pubmed: 28635639
Clin Colorectal Cancer. 2020 Dec;19(4):256-262.e2
pubmed: 32919890
PLoS One. 2014 May 30;9(5):e98528
pubmed: 24879338
J Mol Diagn. 2022 Oct;24(10):1064-1066
pubmed: 35944596
Radiol Oncol. 2019 Sep 24;53(3):265-274
pubmed: 31553708
Crit Rev Oncol Hematol. 2022 Oct;178:103776
pubmed: 35934262
Cancer. 2018 Apr 1;124(7):1358-1373
pubmed: 29338072
J Clin Oncol. 2017 Feb;35(4):446-464
pubmed: 28129524
ESMO Open. 2020 Sep;5(5):e000911
pubmed: 32988996
Curr Probl Cancer. 2018 Nov;42(6):560-571
pubmed: 30100092
Curr Opin Oncol. 2022 Sep 1;34(5):570-574
pubmed: 35943440
Am J Clin Pathol. 2019 Jun 5;152(1):97-108
pubmed: 31115453
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14
pubmed: 35580290
Breast Cancer Res. 2020 Jan 31;22(1):15
pubmed: 32005279
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Nat Med. 2021 Nov;27(11):1899-1903
pubmed: 34764486
Adv Anat Pathol. 2019 Jul;26(4):270-279
pubmed: 30932972
Int J Mol Sci. 2021 Jun 24;22(13):
pubmed: 34202896
Diagnostics (Basel). 2021 Feb 18;11(2):
pubmed: 33670699
Genes (Basel). 2020 Jun 28;11(7):
pubmed: 32605290
Oncologist. 2021 Jul;26(7):e1161-e1170
pubmed: 33844372
Cancer Cell Int. 2021 May 17;21(1):266
pubmed: 34001143
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
Expert Opin Investig Drugs. 2022 Jun;31(6):593-605
pubmed: 35311430
Pathol Oncol Res. 2022 Jul 13;28:1610360
pubmed: 35911441
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biomark Med. 2021 Feb;15(2):135-138
pubmed: 33442995
Mod Pathol. 2013 Jun;26(6):816-24
pubmed: 23348899
World J Gastroenterol. 2016 Sep 21;22(35):7926-37
pubmed: 27672288
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Immunotherapy. 2013 Dec;5(12):1267-9
pubmed: 24283833
Cancer Discov. 2015 Aug;5(8):832-41
pubmed: 26243863
Clin Colorectal Cancer. 2018 Sep;17(3):198-205
pubmed: 29866615
Pharmaceuticals (Basel). 2021 Aug 31;14(9):
pubmed: 34577584
Cancer Invest. 2004;22(6):858-65
pubmed: 15641483
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
J Clin Oncol. 2022 Sep 20;40(27):3205-3221
pubmed: 35759724
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
Cancer Biol Ther. 2015;16(12):1726-37
pubmed: 26553611
Curr Opin Oncol. 2022 Jul 1;34(4):382-388
pubmed: 35730499
Front Oncol. 2021 Mar 25;11:644737
pubmed: 33842357
Br J Cancer. 2019 Nov;121(10):809-818
pubmed: 31607751
Lancet Oncol. 2021 Jun;22(6):779-789
pubmed: 33961795
Breast Cancer Res. 2014 Apr 02;16(2):R33
pubmed: 24693969
Cancer Treat Rev. 2020 Nov;90:102089
pubmed: 32889360
Immunotherapy. 2022 Aug;14(11):885-902
pubmed: 35694998
Mod Pathol. 2015 Nov;28(11):1481-91
pubmed: 26449765
Front Mol Biosci. 2022 Mar 15;9:834651
pubmed: 35372498
Bosn J Basic Med Sci. 2021 Feb 01;21(1):1-4
pubmed: 32530388
Lancet Oncol. 2016 Jun;17(6):685-686
pubmed: 27108244
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2):
pubmed: 29438965
Surg Pathol Clin. 2020 Sep;13(3):485-502
pubmed: 32773196
Lancet Oncol. 2018 Nov;19(11):1434-1435
pubmed: 30507475
Nat Commun. 2020 Jul 20;11(1):3644
pubmed: 32686686
Ann Oncol. 2018 May 1;29(5):1108-1119
pubmed: 29659677